1. Home
  2. Directory
  3. Louisiana
  4. Baton Rouge
  5. Surgery
  6. NPI Profile
  7. Prescriptions 1891739009

DR. CECILIA M CUNTZ MD
Prescription History 1891739009
Surgery in Baton Rouge, LA

NPI Status: Active since June 16, 2006

Contact Information

500 RUE DE LA VIE ST STE 305
BATON ROUGE, LA
ZIP 70817
Phone: (225) 216-1118
Fax: (225) 216-1119

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. CECILIA M CUNTZ MD, an active Surgery specialist practicing in Baton Rouge, LA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 107 documented patient claims. Among these therapy options, the most frequently utilized medication is Hydrocodone-Acetaminophen, which accounts for 56 claims alone.

Medication Index

A
H
V
No matching medications currently found on file.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: General Surgery
Provider Metrics Summary
Total Claims 36
30-Day Fills 96.0
Days Supply 2,880
LA State Average Benchmarks
Peer Average Claims60.0
Peer Average 30-Day Fills124.4
Peer Average Days Supply3,692
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,219.43 across this reporting matrix range.

Provider Avg Cost Per Claim

$33.87

State Avg Cost Per Claim

$21.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Hydrocodone-Acetaminophen

Generic Formulation: Hydrocodone/AcetaminophenSpecialty: General Surgery
Provider Metrics Summary
Total Claims 56
30-Day Fills 56.0
Days Supply 254
LA State Average Benchmarks
Peer Average Claims114.0
Peer Average 30-Day Fills114.8
Peer Average Days Supply2,386
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 50.9% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $268.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.79

State Avg Cost Per Claim

$17.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination medication is used to relieve moderate to severe pain. It contains an opioid pain reliever (hydrocodone) and a non-opioid pain reliever (acetaminophen). Hydrocodone works in the brain to change how your body feels and responds to pain. Acetaminophen can also reduce a fever.

Venlafaxine Hcl Er

Generic Formulation: Venlafaxine HclSpecialty: General Surgery
Provider Metrics Summary
Total Claims 15
30-Day Fills 23.0
Days Supply 690
LA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills69.6
Peer Average Days Supply2,044
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 63.4% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $281.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$18.76

State Avg Cost Per Claim

$21.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Venlafaxine is used to treat depression, anxiety, panic attacks, and social anxiety disorder (social phobia). It may improve your mood and energy level and may help restore your interest in daily living. It may also decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. Venlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. CECILIA M CUNTZ MD provides transparency into local medical care patterns within Baton Rouge, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Surgery** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.